Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $415 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $415.
January 09, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reaffirms an Overweight rating on Vertex Pharmaceuticals with a $415 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst, along with the maintenance of a high price target, suggests a strong vote of confidence in Vertex Pharmaceuticals. This can lead to increased investor optimism and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100